<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213914</url>
  </required_header>
  <id_info>
    <org_study_id>H-09-046</org_study_id>
    <secondary_id>W81XWH-09-2-0194</secondary_id>
    <secondary_id>Combat Casualty Grant</secondary_id>
    <nct_id>NCT01213914</nct_id>
  </id_info>
  <brief_title>Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)</brief_title>
  <acronym>RESCUE</acronym>
  <official_title>The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Burn Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Army Institute of Surgical Research</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampa General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington Hospital Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maricopa Integrated Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tennessee Health Science Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Doctors Hospital-Joseph M Still Burn Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>United States Army Institute of Surgical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine if High-Volume Hemofiltration in addition to
      'contemporary' care will result in an improvement of select clinical outcomes when compared
      to 'contemporary' care alone in the treatment of critically ill patients with ARF secondary
      to septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute renal failure (ARF) is a common and devastating complication in critically ill burn
      patients with mortality reported to be between 80 and 100%.(3-7) Despite recent advances in
      burn care, the unacceptably high mortality rate in this subgroup has not changed over time.
      The pathogenesis of ARF in burns, similar to other critically ill populations, is often
      multi-factorial with one major component being sepsis induced ischemic tubular necrosis.
      Thus, ARF secondary to septic shock is a common and devastating condition in the burn ICU.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vasopressor dependency index</measure>
    <time_frame>first 48 hours</time_frame>
    <description>Vasopressor dependency index = MAP/Inotropic score • This index will correct for the inter-center variability that exists with regards to the point (minimum MAP) at which vasopressors are initiated or weaned off. Thus, this eliminates the need to 'standardize' starting/stopping criteria of vasopressors.
Modified Inotropic index (30) = (dopamine dose X1)+(dobutamine dose X1)+(epi doseX100)+(norepi doseX100)+(phenylephrine doseX100)+(vasopressin doseX100)
• All units recorded at each time point in mcg/kg/min
Mean Arterial Pressure (mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2 ratio and Oxygenation index</measure>
    <time_frame>first 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressors-free days</measure>
    <time_frame>first 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>14 days, 28 days, and discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU days</measure>
    <time_frame>Total number of days in ICU from date of Therapy Initiated through discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>First 28 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal loss (need for long term renal replacement therapy)</measure>
    <time_frame>greater than 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Burns</condition>
  <condition>Hemofiltration</condition>
  <condition>Kidney Failure, Acute</condition>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>High-volume hemofiltration at 70ml/kg/hr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paired randomization into four groups via central randomization center. Group 1: age 18-65 and &lt;40%TBSA Group 2: age 18-65 and &gt;40%TBSA Group 3: age &gt;65 and &lt;40%TBSA Group 4: age &gt;65 and &gt;40%TBSA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contemporary care via consideration of the Burn-Specific Sepsis Bundle adapted form the most recent Surviving Sepsis campaign recommendations and specifically modified to our patient population.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>An FDA approved continuous renal replacement device</intervention_name>
    <description>70ml/kg/hr for treatment group for 48 hours with the following requirements:
double lumen dialysis catheter should be placed in the internal jugular or femoral vein
Anticoagulation will be determined by prescribing physician
Use of 1.4 m2 or larger biocompatible synthetic hollow-fiber dialysis membrane that is changed every 24 hours
Blood flow rate will be set to ensure a filtration fraction of no more than 25%
Monitoring for electrolytes (specifically K+, Mg, Ca, and phos) during HVHF must be performed at least every 6 hours
Replacement fluids will be bicarbonate-buffered with appropriate adjustments when citrate-anticoagulation is utilized
All antibiotics will be dose adjusted for renal replacement therapy</description>
    <arm_group_label>High-volume hemofiltration at 70ml/kg/hr</arm_group_label>
    <other_name>High volume hemofiltration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Both groups will receive 'contemporary' care via consideration of the Burn-specific Sepsis Bundle adapted from the most recent Surviving Sepsis Campaign (SSC) (1) recommendations and specifically modified to our patient population</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Standard of care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients admitted to the burn intensive care unit (ICU) with burns of any
             size

          -  Acute renal failure as previously defined by the Veterans Affairs/ National Institutes
             of Health (VA/NIH) Acute Renal Failure Trial Network study investigators(2)

          -  Patient is &gt; 48 hours post-burn and in Septic Shock

          -  Patients 18 or older

          -  Patient/legally authorized representative willing to provide consent

        Exclusion Criteria:

          -  Age &lt;18

          -  Non-thermal injury (exfoliating skin disorders or necrotizing fasciitis)

          -  Pre-admission diagnosis of end stage renal failure

          -  Patients already on renal replacement therapy for more than 24 hours

          -  Patient not expected to survive more than 24 hours after randomization.

          -  Pregnancy

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin K Chung, MD</last_name>
    <role>Study Chair</role>
    <affiliation>United States Army Institute of Surgical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amy M Sprague, MD</last_name>
    <role>Study Director</role>
    <affiliation>Doctors Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Burn Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Burn Center at Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital-Joseph M Still Burn Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Medical Center at Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center-Burn Center Parkland Health</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Army Institute of Surgical Research</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008 Jul 3;359(1):7-20. doi: 10.1056/NEJMoa0802639. Epub 2008 May 20. Erratum in: N Engl J Med. 2009 Dec 10;361(24):2391.</citation>
    <PMID>18492867</PMID>
  </reference>
  <reference>
    <citation>Leblanc M, Thibeault Y, Quérin S. Continuous haemofiltration and haemodiafiltration for acute renal failure in severely burned patients. Burns. 1997 Mar;23(2):160-5.</citation>
    <PMID>9177886</PMID>
  </reference>
  <reference>
    <citation>Greenhalgh DG, Saffle JR, Holmes JH 4th, Gamelli RL, Palmieri TL, Horton JW, Tompkins RG, Traber DL, Mozingo DW, Deitch EA, Goodwin CW, Herndon DN, Gallagher JJ, Sanford AP, Jeng JC, Ahrenholz DH, Neely AN, O'Mara MS, Wolf SE, Purdue GF, Garner WL, Yowler CJ, Latenser BA; American Burn Association Consensus Conference on Burn Sepsis and Infection Group. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007 Nov-Dec;28(6):776-90.</citation>
    <PMID>17925660</PMID>
  </reference>
  <reference>
    <citation>Azevedo LC, Park M, Schettino GP. Novel potential therapies for septic shock. Shock. 2008 Oct;30 Suppl 1:60-6. doi: 10.1097/SHK.0b013e318181a425. Review.</citation>
    <PMID>18704007</PMID>
  </reference>
  <reference>
    <citation>Ratanarat R, Permpikul C. Roles of extracorporeal blood purification in sepsis. J Med Assoc Thai. 2007 May;90(5):1021-31.</citation>
    <PMID>17596062</PMID>
  </reference>
  <reference>
    <citation>Chung KK, Lundy JB, Matson JR, Renz EM, White CE, King BT, Barillo DJ, Jones JA, Cancio LC, Blackbourne LH, Wolf SE. Continuous venovenous hemofiltration in severely burned patients with acute kidney injury: a cohort study. Crit Care. 2009;13(3):R62. doi: 10.1186/cc7801. Epub 2009 May 1.</citation>
    <PMID>19409089</PMID>
  </reference>
  <reference>
    <citation>Piccinni P, Dan M, Barbacini S, Carraro R, Lieta E, Marafon S, Zamperetti N, Brendolan A, D'Intini V, Tetta C, Bellomo R, Ronco C. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med. 2006 Jan;32(1):80-6. Epub 2005 Nov 18.</citation>
    <PMID>16328222</PMID>
  </reference>
  <reference>
    <citation>Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000 Jul 1;356(9223):26-30.</citation>
    <PMID>10892761</PMID>
  </reference>
  <reference>
    <citation>Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, Hanique G, Matson JR. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 2000 Nov;28(11):3581-7.</citation>
    <PMID>11098957</PMID>
  </reference>
  <reference>
    <citation>Wagener G, Gubitosa G, Wang S, Borregaard N, Kim M, Lee HT. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am J Kidney Dis. 2008 Sep;52(3):425-33. doi: 10.1053/j.ajkd.2008.05.018. Epub 2008 Jul 23. Erratum in: Am J Kidney Dis. 2008 Oct;52(4):810.</citation>
    <PMID>18649981</PMID>
  </reference>
  <reference>
    <citation>Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009 Jun 17;301(23):2445-52. doi: 10.1001/jama.2009.856.</citation>
    <PMID>19531784</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burns</keyword>
  <keyword>Hemofiltration</keyword>
  <keyword>Vasopressins</keyword>
  <keyword>Kidney Failure Acute</keyword>
  <keyword>Shock, Septic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Burns</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

